- 4 hrs ago Is It Safe To Get A Tattoo While On Periods?
- 6 hrs ago Yogini Ekadashi 2022: Date, Time, Puja Muhurat, Vrat Katha, Remedies And Significance
- 8 hrs ago Monkeypox: We Have Vaccines And Drugs To Treat It
- 8 hrs ago Puri Rath Yatra 2022: Date, Time, Legends, Celebration, History And Significance
- Finance Govt Asks To Share Only Masked Aadhaar; Here Is How You Can Download It
- News Vat Savitri Vrat 2022: Date, Time, Fasting Rules, Method and Importance
- Sports Italy vs Argentina, Finalissima 2022: Date, Kick-off Time in India, Teams, Telecast & Live Streaming Info
- Movies Kamal Haasan Meets Rajinikanth Ahead Of Vikram Release; Lokesh Kanagaraj Shares Pictures
- Technology This WhatsApp Scam Can Get Control Of Your Phone
- Travel One Day Outing From Nagpur: Maharashtra - Places To Visit
- Automobiles Hindustan Motors To Produce Electric Scooters & Cars; This Includes The New Ambassador EV
- Education RRB NTPC CBT 2 Level 2, 3, And 5 Exam Schedule Released, Check Exam Dates Here
The price of Covishield and Covaxin, the COVID-19 vaccines which are expected to soon get regular market approval from India's drug regulator, is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150, official sources said. According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable.
As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the coAn Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation on January 19 recommended granting regular market approval to COVID vaccines Covishield and Covaxin for use in the adult population subject to certain conditions.
"The NPPA has been asked to work towards capping the price of the vaccines. The price is likely to be capped at Rs 275 per dose along with an additional service charge of Rs 150," an official source said.
Prakash Kumar Singh, the director (government and regulatory affairs) at Serum Institute of India, had submitted an application to the Drugs Controller General of India on October 25 seeking regular market approval for its Covishiled vaccine.
A couple of weeks ago, V Krishna Mohan, the whole-time director at Bharat Biotech, submitted complete information on the chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
COVID vaccine - Photo by DW News / Getty Images.
- wellnessIndia Records 2,685 Fresh Covid-19 Cases, 33 Deaths
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessHypertension Most Common Co-Morbidity: Delhi Hospital Study On Covid-19 Patients
- womenWHO Honours 1 Million ASHA Women For COVID-Care Role
- wellnessAir Pollution Linked With More Severe COVID-19: Study
- wellnessOmicron Subvariants BA.4 And BA.5 In India: What You Need To Know
- wellnessHaven't Had Covid-19 Yet? It Could Be More Than Just Luck
- disorders cureWhat Is Geographic Tongue? Is It Related To COVID? Read About The Causes And Symptoms
- wellnessWhy People With Lung Disorder Face Risk Of Severe Covid-19 Found
- wellnessIndia's First mRNA Vaccine Against COVID: 90% Effective; Can Be Used For Malaria, Dengue Etc.
- wellnessOestrogen Treatment Linked With Reduced Covid Mortality: Study
- wellnessTrained Sniffer Dogs May Accurately Detect COVID Infected Airport Passengers: Study